For the quarter ending 2025-09-30, SRZN had $46,770K increase in cash & cash equivalents over the period. -$24,501K in free cash flow.
| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -58,867 |
| Depreciation and amortization | 492 |
| Stock-based compensation | 2,833 |
| Non-cash operating lease expense | 1,351 |
| Loss on amendment and cancellation of warrants | 2,073 |
| Loss on execution of the 2025 pipe | 71,084 |
| Transaction costs allocated to pre-funded warrants and warrants issued in connection with the 2025 pipe and 2024 pipe | 2,777 |
| Change in fair value of tranche liability | 7,112 |
| Change in fair value of warrant liabilities | -35,774 |
| Loss on issuance of common stock, pre-funded warrants and warrants in the 2024 pipe | 0 |
| Gain on settlement of tranche liability | 1,117 |
| Non-cash consideration received in connection with research service revenue | 692 |
| Gain on foreign currency remeasurement | 278 |
| Accounts receivable | 0 |
| Accounts receivable -related party | -251 |
| Prepaid expenses and other current assets | -82 |
| Other assets | -54 |
| Accounts payable | 232 |
| Accrued and other liabilities | -434 |
| Operating lease liabilities | -1,387 |
| Net cash used in operating activities | -24,432 |
| Purchases of property and equipment | 69 |
| Net cash used in investing activities | -69 |
| Proceeds from issuance of common stock, pre-funded warrants and warrants in the 2025 pipe and 2024 pipe, net of transaction costs | 71,201 |
| Proceeds from issuance of common stock under employee stock purchase plan | 61 |
| Proceeds from issuance of common stock upon exercise of options | 9 |
| Net cash provided by financing activities | 71,271 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 46,770 |
| Cash and cash equivalents at beginning of period | 35,253 |
| Cash and cash equivalents at end of period | 82,023 |
Surrozen, Inc. DE (SRZN)
Surrozen, Inc. DE (SRZN)